

NZX and Media Release

20 July 2020

NZX Limited

WELLINGTON

## **Truscreen Director Nominations Closing Date**

Truscreen Limited (NZX: TRU) advises that the closing date for director nominations is 5pm on Friday, 31 July 2020.

Nominations may only be made by a shareholder entitled to attend and vote at the annual meeting which will be held on 3 September 2020. The nomination must be accompanied by the consent, in writing, of the person nominated and should contain a brief curriculum vitae of the nominee.

Nominations should be addressed to:

Guy Robertson

TruScreen Chief Financial Officer

Email: [guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com) or [info@truscreen.com](mailto:info@truscreen.com)

-ENDS-

---

For more information visit [www.truscreen.com](http://www.truscreen.com) or contact Guy Robertson, Truscreen Chief Financial Officer, e-mail: [guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

## About TruScreen:

Watch our video on TruScreen: <http://truscreen.com/truscreen-the-company/truscreen-ultra-video/>

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests including failed samples, poor patient follow up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen target market is developing countries where no large scale cervical cancer screening programs and infrastructure are in place, such as; China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is EC certified for use throughout Europe and CFDA approved for sale in China. Truscreen gained recognition from Global NGO's WHO and Unitaid in a joint Cervical Cancer Technology Landscape released at the 72<sup>nd</sup> World Health Assembly.

For more information, visit our website at [www.truscreen.com](http://www.truscreen.com)